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ASSOCIATION OF YOUNGER AGE WITH POOR GLYCAEMIC AND CHOLESTEROL
CONTROL IN ASIANS WITH TYPE-2 DIABETES IN SINGAPORE
Toh MPHS, Wu CX, Heng BH
National Healthcare Group, Singapore
OBJECTIVES: The National Healthcare Group Polyclinics (NHGP) is a group of 9
public sector primary care clinics in Singapore. This study examines the factors
associated with poor glycaemic control in Asian patients with type 2 diabetes mel-
litus (T2DM) in Singapore. METHODS: This is a cross-sectional study of patients
with T2DM who attended the same clinic in 2009 for the treatment of diabetes.
Demographic characteristics, medical diagnosis, clinical parameters and labora-
tory results were extracted from the group’s Diabetes Registry (CDMS). Glycaemic
(HbA1c) and cholesterol (LDL-c) control were compared with age and logistic re-
gression analysis was applied to study the factors associated with poor glycaemic
control usingHbA1c cut-off at 8%. RESULTS:Among the 58,057 T2DMpatientswere
more females (54%), disproportionately more Indians (13%) and fewer Chinese
(71%) than the general population. Both HbA1c and LDL-c improved with age. The
mean HbA1c decreased gradually from 8.161.74% (40 years) to 6.940.99% (80
years) while mean LDL-c dropped from 2.840.80 to 2.560.70. The Indian and
Malay groups had significantly poorer glycaemic control compared to the Chinese,
AdjOR 1.66 (95%CI:1.56-1.77) and 1.53 (95%CI:1.43-1.63) respectively. Other signifi-
cant predictors of poor glycaemic control included the male gender (AdjOR 1.19;
95%CI 1.19:1.14-1.25), presence of maculopathy or retinopathy, peripheral vascular
disease, coronary heart disease, heart failure, and being on insulin therapy (AdjOR
8.00; 95%CI:7.54-8.48). Patients with poor LDL-c (4.0 mmol/L) were 4.2 times the
odds of having poor glycaemic control (95%CI:3.78-4.66) while those with Grade 2
hypertension were 1.5 times (95%CI:1.35-1.76). CONCLUSIONS: Younger T2DM pa-
tients had poorer glycaemic and cholesterol control than older patients. Thosewith
poor glycaemic control also had corresponding poorer cholesterol and blood pres-
sure control. These patients had a higher lifetime risk of developing micro- and
macro-vascular complications and should be treated much more aggressively to
achieve “optimal” glycaemic and cholesterol control.
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FACTORS ASSOCIATED WITH ROUTINE PROPER MONITORING OF DIABETES
CARE AMONG THE NON-INSTITUTIONALIZED POPULATION IN THE UNITED
STATES: A RETROSPECTIVE ANALYSIS OF THE 2007 MEDICAL EXPENDITURE
PANEL SURVEY (MEPS)
Zhao Y, Fonseca V, Shi L
Tulane University, New Orleans, LA, USA
OBJECTIVES: This study aimed to examine the rate and predictors of diabetes
monitoring in the US. METHODS: This cross-sectional retrospective study was
conducted on a representative, non-institutionalized sample of the United States
population (the 2007 Household Component (HC) of the MEPS). According to the
American Diabetes Association (ADA) 2007 practice guidelines, proper provider
monitoring is defined as at least two A1c tests, one eye and one foot examination
annually. Health status was measured by SF-12. A logistic regression model was
used to examine the predictors of proper monitoring. Differences in health status
and medical expenditures between patients with and without proper monitoring
were examined using t-tests. Estimates were weighted to the total population
(WTP). RESULTS: Among 1,747 (WTP: 19,320,394) patients with diabetes, 80.64%
had at least two A1c tests; 63.29% had an eye examination; and 67.51% had a foot
examination. Thus, 63.36% patients (WTP: 14,065,289) received proper diabetes
monitoring. Older patients (OR:1.021, 95% confidence interval (CI):1.012-1.030),
non-Hispanic Caucasians compared with African Americans (OR:1.236, 95% CI:
0.933-1.636), patients with a higher education level (OR:1.211, 95% CI:1.056-1.390),
insurance coverage (OR:2.216, 95% CI:1.408-3.486), use of oral anti-diabetic drugs
(OR:2.935, 95% CI:2.131-4.042) and insulin (OR:3.453, 95% CI:2.477-4.814) were more
likely to undergo the proper monitoring. Well monitored patients had a higher
SF-12Mental Component Summary score (50.090.37 vs. 48.510.45, p0.05), but a
lower SF-12 Physical Component Summary score (39.950.34 vs. 42.280.47,
p0.05). Properly monitored patients spent significantly more on total health care
services ($5,243), outpatient visits ($1,023), and medications ($1,204), respec-
tively (all p-values0.05). CONCLUSIONS: In the United States, nearly 40% patients
with diabetes do not receive the proper diabetes monitoring according to the ADA
guidelines. In addition to racial and socioeconomic disparities, anti-diabetics/in-
sulin use,mental health status, physical health status, andhealth care expenditure
were associatedwith performingmonitoring. Cost-benefit of long-termmonitoring
should be studied.
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OBJECTIVES: The objective of this study was to determine the economic impact of
a pharmacy program to convert insulin utilization from multi-dose vials to pen
delivery systems on a long termcare facility chain.METHODS: Purchasing datawas
obtained at the patient level for basal and short acting insulins from a chain of 75
skilled nursing facilities for the 12 month period ending June 2010. Data included
date dispensed, amount dispensed (mls), delivery system (pen or vial) and amount
paid to the dispensing pharmacy. The insulin cost per patient-day for each month
was calculated as total acquisition cost for the month divided by the number of
patient-days. The insulin cost per patient-day for each stay was calculated as the
total insulin acquisition cost divided by the length of stay in days. The mean cost
per patient-day for each patient stay subset based on payer type, length of stay and
delivery system used (pen only, vial only, pen and vial combination) was
calculated. RESULTS: There were 2,405 inpatient stays over the 12 month period,
70% covered by Medicare and 29% by Managed Care. Two-thirds of Medicare stays
and over three-fourths of managed care stays were 30 days or less. Pen device
purchases increased fromunder 1% to almost 35% of total purchases over the study
period duringwhich the insulin cost per day declined fromover $10 per patient-day
to $4. The cost per day for vial-only stays ($7.84) and combination vial and pen stays
($7.79) were 72% higher than pen-only stays ($4.54), despite a 39% price premium
per milliliter for pens. Differences were most marked for lengths of stay under 30
days.CONCLUSIONS:The increase in pen device usewas associatedwith amarked
decrease in insulin costs on a patient-day basis, particularly for lengths of stay
under 30 days.
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BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF SAXAGLIPTIN IN THE
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OBJECTIVES: To estimate the budget impact of Saxagliptin introduction as a treat-
ment option for patients with type 2 diabetes mellitus (DM2) compared to the
present situation. METHODS: An MS Excel-based budget impact model assuming
coverage for onemillion people. The time horizonwas three years and the analysis
perspective was that of the public health care system in Chile. Pharmaceutical
expenses of antidiabetic agents were analyzed, excluding other medical costs. The
cost of antidiabetic agents was based upon list prices adjusted to co-payments,
expressed in 2009 US dollars; the Saxagliptin price was considered to be equal to
the sitagliptin price. The market share of the different drugs was based upon mar-
ket studies and data provided by Bristol Myers Squibb. The budget impact is re-
ported in terms of annual budget impact, per member per month (PMPM). The cost
of pioglitazone and rosiglitazone related cardiovascular events, as well as that of
sulphonylureas related hypoglycemia events were expressed as rates of occur-
rence per patient per year and cost per occurrence. RESULTS: The estimated net
budget impact for the introduction of Saxagliptin was US$ 70,723, US$ 162,885 and
US$ 251,574 for the first, second and third year respectively; the cumulative net
budget impact was US$ 485,181. PMPM was US$ 0.0059, US$ 0.0136 and US$ 0.0209
each year, respectively. The cumulative impact in the total annual budget for an-
tidiabetics represented an increase of 4.22%. CONCLUSIONS: The budget impact of
adding Saxagliptin in a population of one million people to the public health care
system in Chile is minimal in patients with DM2. The rise in pharmaceutical ex-
penses derived from introducing Saxagliptin into the formulary is balanced by
savings in terms of reduction of adverse events related to thiazolidinediones and
sulfonylureas, as well of lowering of insulin requirements in an extended time
horizon.
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A COST COMPARISON OF A BASAL BOLUS REGIMEN (INSULIN GLARGINE AND
INSULIN GLULISINE) WITH A CONVENTIONAL PRE-MIXED INSULIN REGIMEN IN
TYPE-2 DIABETES PATIENTS – THE GINGER STUDY
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OBJECTIVES: This cost analysis, based on the results of the GINGER study, aimed to
investigatewhether an intensified insulin regimen is better value than a 2 injection
per day conventional regimen. METHODS: GINGER was a 52 week multi-national
study in 310 T2D patients on insulin for an average of 5 years with poor glycaemic
control. It compared mealtime rapid-acting insulin glulisine (IGL) and insulin
glargine (IG) once daily with 2 injections per day of pre-mixed insulin. Use of IGL/IG
resulted in a change of HbA1C from baseline to endpoint of 1.31% and 0.80% for
pre-mixed insulin. Costs were calculated from a UK NHS perspective using MIMS
November 2010 prices. Insulin costs were based on the use of IGL/IG (Apidra Solo-
Star and Lantus SoloStar) and biphasic insulin aspart (BIA, NovoMix 30 FlexPen)
prefilled disposable injection devices. It was assumed that a newneedle, lancet and
blood glucose test strip were used for each injection with a 2U priming dose of
insulin before each injection. RESULTS: The annual drug cost per patient on IGL/IG
was higher than BIA at £692 and £612 respectively with the cost of metformin
similar for both groups. The cost of needles, lancets and test stripswasmuch lower
for BIA at £329 compared with £537 for the IGL/IG group. Overall the total annual
cost per patient for the IGL/IG group was £1243 compared with £957 for BIA. Over
the 52 weeks the relative cost of a 1% reduction in HbA1C was £949 for IGL/IG and
£1197 for BIA, a 1mmol/l reduction in FPG was £518 with IGL/IG and £563 with BIA.
Sensitivity analyses replacing BIA by insulin lispro or isophane insulin gave very
similar results. CONCLUSIONS: A similar reduction in HbA1C and FPG can be
achieved at a relatively lower cost with IGL/IG in comparison with BIA.
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INSULIN GLARGINE PLUS OHAS VERSUS BIPHASIC INSULIN IN TYPE-2
DIABETES – A COST COMPARISON
Tilling C1, Owens D2, Keech M3
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